Publications
Export 13 results:
Filters: Keyword is Antipsychotic Agents [Clear All Filters]
, “[Psychoeducation for overweight patients with psychiatric disorders: The Wellness program developed in Quebec].”, Encephale, vol. 42, no. 3, pp. 201-7, 2016.
, “Transcranial Direct Current Stimulation for the Treatment of Refractory Symptoms of Schizophrenia. Current Evidence and Future Directions.”, Curr Pharm Des, vol. 21, no. 23, pp. 3373-83, 2015.
, “[Cognitive-behavioural therapy in early psychosis: an open study in a clinical setting].”, Can J Psychiatry, vol. 56, no. 1, pp. 51-61, 2011.
, “Anhedonia and social adaptation predict substance abuse evolution in dual diagnosis schizophrenia.”, Am J Drug Alcohol Abuse, vol. 34, no. 1, pp. 75-82, 2008.
, “Differential RNA expression between schizophrenic patients and controls of the dystrobrevin binding protein 1 and neuregulin 1 genes in immortalized lymphocytes.”, Schizophr Res, vol. 100, no. 1-3, pp. 281-90, 2008.
, “Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy.”, J Psychopharmacol, vol. 22, no. 3, pp. 262-9, 2008.
, “Deficient relational binding processes in adolescents with psychosis: evidence from impaired memory for source and temporal context.”, Cogn Neuropsychiatry, vol. 12, no. 6, pp. 511-36, 2007.
, “Possible association of the pro-melanin-concentrating hormone gene with a greater body mass index as a side effect of the antipsychotic olanzapine.”, Am J Med Genet B Neuropsychiatr Genet, vol. 144B, no. 8, pp. 1063-9, 2007.
, “Processing spatial-temporal information in recent-onset schizophrenia: the study of short-term memory and its susceptibility to distraction.”, Brain Cogn, vol. 64, no. 3, pp. 201-7, 2007.
, “Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.”, J Clin Psychiatry, vol. 65, no. 4, pp. 557-64, 2004.
, “First person account: Susan's cello.”, Schizophr Bull, vol. 28, no. 1, pp. 187-9, 2002.
, “Atypical antipsychotics and cardiovascular risk in schizophrenic patients.”, J Clin Psychopharmacol, vol. 21, no. 1, pp. 110-1, 2001.
, “Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. The Quebec Schizophrenia Study Group.”, J Clin Psychopharmacol, vol. 20, no. 3, pp. 295-304, 2000.
